Releases
6. January, 2022
Changes to the Board of Directors – welcome to Rachel
Cessatech has appointed Rachel Curtis Gravesen as Observer to the Board of Directors with...
Releases
22. December, 2021
Cessatech successfully raises DKK 24.3 million through warrant exercise
During the period 25 November – 16 December 2021, holders of TO 1 have...
Releases
25. November, 2021
Exercise warrants of series TO1 before 14 Dec
In connection with the Company’s IPO in November/December 2020, Cessatech issued units (shares and...
Releases
2. November, 2021
First US patent covering CT001
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11.160.799...
Releases
20. August, 2021
Cessatech reports first patient dosed in pharmacokinetic trial in children of lead product candidate
Clinical trial 0206 will investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical...
Releases
19. August, 2021
Second quarter report Q2-2021 – planning for the pivotal trials
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...
Releases
29. June, 2021
Cessatech announces new Chairman of the Board – getting ready for the pivotal studies
The Board of Directors has appointed Adam Steensberg as new Chairman of the...
Releases
31. May, 2021
Last subject dosed in bioavailability trial 0204 of lead product candidate
Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports...
Releases
14. May, 2021
Cessatech A/S is awarded IPO of the year 2020 by independent editorial Affärsvärlden
Among the 26 micro-companies, the IPO guide’s reviewers found an average of 2.9 flags....
Releases
19. April, 2021
First quarter report Q1-2021 – ‘one down, two to go’ of the major milestones of 2021
Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...
Releases
24. March, 2021
Cessatech reports first subject dosed in bioavailability trial of lead product candidate
Clinical trial 0204 in healthy volunteers will investigate the absolute bioavailability of CT001. Primary...
Releases
9. March, 2021
Cessatech A/S is awarded Best Medical Treatment IPO Nordics in 2020 by independent editorial
CFI.co – a journal and online resource reporting on business, economics and finance –...
Want to see all releases?
To see all releases including those not listed here, go to our filings and reports.